Navigation Links
UC San Diego researchers identify potential new drug candidates to combat 'bird flu'
Date:7/2/2008

ug designs, said McCammon, one of the pioneers in the field. For example, the route to the development of raltegravir, an anti-integrase inhibitor recently approved by the U.S. Food and Drug Administration to combat HIV, was discovered in McCammon's lab.

"The treatment of receptor flexibility with molecular dynamics simulations played a critical role in understanding the mechanism of action for this new class of inhibitors," said McCammon, a professor of Pharmacology at UC San Diego.

In their latest work, the scientists conducted a "virtual screen" of an ensemble of 1,883 compounds selected from the National Cancer Institute Diversity Set, using a computational tool called AutoDock that predicts how small molecules, such as drug candidates, bind to a receptor of a known three-dimensional structure. The goal was to try to determine which compounds fit best into the "hot pocket" region of N1. Generally, compounds that most easily bind to the site are considered to be top hits for validation and further optimization as drug candidates.

Five other compounds known to experimentally bind to avian influenza N1 were also screened, including drugs now available or in clinical trials.

The results were intriguing. About 27 compounds showed significant promise, all having potentially the same or stronger bonding affinity than current anti-flu drugs now available, including Tamiflu and Relenza. Several looked like particularly good candidates, Amaro said, since they bound to both the regular active site and an additional side pocket that opened during the computer simulation.

"The general idea is that we will be able to make a better drug through the strategic targeting of multiple active site pockets," said Amaro.

Added Cheng, former Pacific Rim Experience for Undergraduate student and NBCR researcher: "Importantly, half of these compounds would have been neglected based on the crystal structure simulations alone. Many of t
'/>"/>

Contact: Warren R. Froelich
froelich@sdsc.edu
858-822-3622
University of California - San Diego
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Glowing films developed by UC San Diego chemists reveal traces of explosives
2. UC San Diego researchers eliminate drug discovery bottleneck
3. Biologists at UC San Diego identify key protein in cells self-eating function
4. San Diego Harbor Police Deploy BIO-key(R) Automated Vehicle Location System
5. UC San Diego begins trading greenhouse gas credits on Chicago Climate Exchange
6. Experimental Biology 2008 meets in San Diego April 5-9
7. UC-San Diego Engineering Honor Society wins most outstanding chapter award
8. UC San Diego physicists tackle knotty puzzle
9. Texas A&M researchers develop tool to study complex clusters of genes
10. Weekends slow weight loss, researchers find
11. Researchers coat titanium with polymer to improve integration of joint replacements
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC San Diego researchers identify potential new drug candidates to combat 'bird flu'
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... soot or black carbon turns out to be ... to carbon dioxide, according to a four-year assessment by an ... soot particles in smoke and smog, contributes about twice as ... 2007 Intergovernmental Panel on Climate Change. "We were surprised at ...
... bacteria and tree, How the protein transport machinery ... Physcomitrella patens is an evolutionary intermediate stage ... have studied how the protein transport system of ... in the chloroplasts of higher plants. They explored ...
... span eight countries from France to Slovenia and harbour an ... found nowhere else. They are widely considered to be ... biodiversity in Europe. But the Alps are not just ... of up to 14 million people and the destination for ...
Cached Biology News:International study: Where there's smoke or smog, there's climate change 2International study: Where there's smoke or smog, there's climate change 3How the protein transport machinery in the chloroplasts of higher plants developed 2How the protein transport machinery in the chloroplasts of higher plants developed 3In search of the big questions: Conserving the European Alps 2In search of the big questions: Conserving the European Alps 3
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 2008 at 9:00 a.m. Eastern ... ... ALSE ) today reports operational and,financial results for the quarter ended ... http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the progress we ...
... Named Contract Manufacturer of Choice, Based on Its ... Based on its recent,analysis of the pharmaceutical ... BioPharma Solutions (BPS) with the 2008 North,American Frost ... Award at,the 2008 Excellence in Healthcare Innovation Awards ...
... Novavax uses strategies to create vaccines for avian flu ... genetically-engineered virus-like particles (VLPs), ROCKVILLE, Md., ... today that its strategy for treating avian flu,through genetically-engineered ... at Cleveland Clinic 6th Annual Medical Innovation,Summit., Novavax, ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 2Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 2Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 4
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
...
Biology Products: